Strategic Divestment to Enhance Portfolio Quality
First REIT has announced a comprehensive divestment strategy for its Indonesian healthcare assets, proposing to sell eight hospitals and three non-hospital properties for S$471.5mn. The purchaser, PT Siloam International Hospitals Tbk, will acquire these assets in the first tranche of what represents a strategic pivot towards developed markets.
Company Overview
First REIT operates as a healthcare-focused real estate investment trust with assets spanning Singapore, Japan, and Indonesia. The REIT specialises in healthcare properties including hospitals and medical facilities across the Asia-Pacific region.
Two-Tranche Divestment Structure
The proposed transaction follows a carefully structured two-phase approach. The initial tranche involves eleven Indonesian assets valued at S$471.5mn, comprising eight hospitals for IDR5.1tn (S$389.2mn) and three non-hospital assets for IDR1.1tn (S$82.4mn). This pricing represents a 2.1% premium over the average of two recent independent valuations.
Additionally, First REIT has secured a put option for the remaining six Indonesian hospitals, valued at S$294.8mn, exercisable until 31 October 2026. This structure provides flexibility whilst ensuring complete exit from the Indonesian market if desired.
Financial Impact and Capital Allocation
The divestment will generate significant financial benefits for unitholders. The S$9.7mn premium over appraised value will be distributed as special dividends over two quarters following completion. The manager has waived its S$2.4mn divestment fee to align with unitholder interests.
Net proceeds of S$464.2mn will primarily reduce debt, with S$362.7mn (78%) allocated to debt repayment. This will dramatically improve the REIT’s leverage profile, reducing aggregate leverage from 42.1% to 16.7%. The remaining debt will largely comprise lower-cost JPY-denominated borrowings.
Strategic Outlook and Research Recommendation
The divestment addresses rental arrears issues whilst enabling capital recycling from non-core assets. First REIT plans to focus on assets in Singapore and Japan whilst pursuing expansion opportunities in developed markets, which offer lower equity risk premiums, reduced debt costs, and more stable currencies.
Phillip Securities Research maintains an ACCUMULATE recommendation with a revised target price of S$0.25, down from S$0.29. The valuation methodology has shifted to 1x FY25 P/NAV from the dividend discount model, reflecting uncertainty over future portfolio composition pending the strategic review.
Frequently Asked Questions
Q: What assets is First REIT proposing to divest?
A: First REIT is proposing to divest eight hospitals and three non-hospital assets in Indonesia for S$471.5mn, with an additional put option for six remaining hospitals at S$294.8mn.
Q: Who is purchasing the Indonesian assets?
A: PT Siloam International Hospitals Tbk (Siloam) is the purchaser of the eight hospitals in the first tranche.
Q: When will the divestment be completed?
A: The divestments are subject to unitholders’ approval at an Extraordinary General Meeting scheduled for June 2026, with targeted completion in August 2026.
Q: How will the proceeds be used?
A: Net proceeds of S$464.2mn will primarily reduce debt (S$362.7mn or 78%), with S$9.7mn distributed as special dividends and the remainder allocated to capital expenditure and working capital.
Q: What is Phillip Securities Research’s recommendation and target price?
A: Phillip Securities Research maintains ACCUMULATE with a lower target price of S$0.25, reduced from the previous S$0.29.
Q: How will the divestment impact leverage?
A: Aggregate leverage would decline significantly to 16.7% from the current 42.1%, assuming completion on 31 December 2025.
Q: What is First REIT’s strategic direction following the divestment?
A: First REIT plans to focus on Singapore and Japan assets whilst transitioning toward developed markets, which offer lower equity risk premiums, lower debt costs, and more stable currencies.
Q: Will unitholders receive any special distributions?
A: Yes, the S$9.7mn premium over appraised value will be distributed as special dividends over two quarters following completion of the divestment.
This article has been auto-generated using AI tools. It is based on a report by a Phillip Securities Research analyst.
Disclaimer
These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products.
Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance.
Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries.
The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries.
Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned.
